Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2026-01-02 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement titled 'Total Voting Rights' issued by Shield Therapeutics plc. It explicitly references the FCA's Disclosure and Transparency Rule 5.6.1, which requires companies to disclose their total number of voting rights and share capital. This is a standard regulatory disclosure filing, not a financial report or a shareholder meeting document. Given it is a standard regulatory notification provided via the RNS (Regulatory News Service), it falls under the RNS category.
2026-01-02 English
FDA approves extension for ACCRUFeR®
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing that the US FDA has approved an extension of the indication for the company's product, ACCRUFeR. This is a corporate announcement regarding a significant regulatory/operational development. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a standard regulatory news announcement, it is classified as RNS.
2025-12-22 English
Block Listing Application
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Shield Therapeutics plc regarding a 'Block Listing Application' to the London Stock Exchange for the issuance of 15,000,000 new ordinary shares. This falls under the category of share issuance or capital changes. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate classification for announcements regarding new share issues or capital structure changes.
2025-12-18 English
Shield Wins Gold at Titan Branding Awards
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS (Reach) service announcing that Shield Therapeutics plc received a 'Gold' award at the Titan Brand Awards. It does not contain financial results, regulatory filings, or any of the specific report types listed. As it is a general corporate announcement regarding a marketing award, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-11 English
Amends Senior Secured Debt Financing
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Shield Therapeutics plc regarding the amendment of its senior secured debt financing, including details on loan facility expansion, interest rate adjustments, and new warrant issuances. This falls under the category of company fundraising and financing activities. While it is distributed via RNS, it is a substantive announcement of a capital structure change rather than a mere report publication notice or a general regulatory filing.
2025-12-03 English
Initiation of a Phase II Clinical Trial in Japan
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) regarding the initiation of a Phase II clinical trial for a pharmaceutical product. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it contains the primary news content itself. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.